Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication
about
Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cellsTyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cellsCCR11 is a functional receptor for the monocyte chemoattractant protein family of chemokinesSynergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effectsRole of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564Differential effects of human immunodeficiency virus isolates on beta-chemokine and gamma interferon production and on cell proliferation.Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction.Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation.Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.The macrophage in HIV-1 infection: from activation to deactivation?Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5.Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidateChemokine receptors: emerging opportunities for new anti-HIV therapies.Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice.CCR5 conformations are dynamic and modulated by localization, trafficking and G protein associationMultimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine.Chemokine receptor 5 is dispensable for innate and adaptive immune responses to Listeria monocytogenes infection.Control of HIV-1 infection by soluble factors of the immune response.Cytokine expression in the colonic mucosa of human immunodeficiency virus-infected individuals before and during 9 months of antiretroviral therapy.Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: Implications for extracranial origin of headache.Pattern and temporal sequence of sulfation of CCR5 N-terminal peptides by tyrosylprotein sulfotransferase-2: an assessment of the effects of N-terminal residuesA CCL8 gradient drives breast cancer cell dissemination.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritisC-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium.Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways.Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.Extracranial origin of headache.Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5.Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function.The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.Chemokines, receptors, and their role in cardiovascular pathology.Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration.The effects of long-term herbal treatment for pediatric AIDS.Lymphotoxin α fine-tunes T cell clonal deletion by regulating thymic entry of antigen-presenting cells.
P2860
Q22003751-6E2C6D8E-0FA5-4E75-93D3-DC2011B60B4CQ22008684-608B9FEF-F22E-4E36-8FE8-A21E93559A7BQ24534959-CB5B37C2-455A-48B5-9CB2-C664BC9394C6Q24633405-877B73A4-86BF-4A7A-9893-A173F8ACC166Q28115490-F47B3A19-1EA3-4060-BAF5-A1DB66F47F9FQ28235478-8D79A9D8-9FB8-4362-BC00-70425FFA0EE7Q28345233-9AB0A563-A2EF-45D0-8724-A7C3FFE4A29FQ33641854-4C7B9C67-9BED-4048-AF6F-FAF8746149EAQ33642021-6B93F5AE-4D13-4A9E-9B6B-D6764F0046E2Q33717470-58E1B95D-09F0-411E-93E5-92D01BC815D1Q33804495-284B12D7-1ADF-4791-A31B-FD68BF944647Q33810779-982E95CD-502B-47A1-981B-C4A9CD7C8117Q33838860-2461DBAB-E0A5-46D0-A97C-26B0A00CE1C4Q34362854-ECF035A9-D79C-4A87-BBF1-6EA1CBABCB0EQ34999818-30D91BAE-3BB5-4D98-B742-89E5C43DAFA9Q35050395-1710F302-DECB-40D3-AC2A-F59BFB49AD98Q35050827-7077BEBE-0465-4BE4-9588-8794C2232E92Q35106596-203B8FD0-70CC-4403-9B19-EE3B77FB2F01Q35129224-664C186A-82F4-4A24-9BD1-C737893E2B08Q35198556-6B9E6A31-329E-4C82-90B8-2708EF32217DQ35550834-D1C0767D-CA95-4B25-8C79-9FE4F11B573FQ35752416-BE28D6D5-EABC-48BB-A799-4C54D692FC55Q36870874-19F720C8-8000-475F-901E-BBA491029A91Q36944764-59D0C57C-9999-44BC-B595-06E954A733B0Q37309197-7D46E739-5A44-430D-858F-8DB53D53035FQ37418545-50852C19-DB2B-4F87-BF57-677005C48E11Q37432097-58D36E74-FDDC-42BA-AAD4-83BD1E36897EQ37456872-BAD325BF-C115-4A82-8E8F-766DCD15ECE1Q37463869-DB0A5BA9-2EB0-41CE-AF40-45526621E5C2Q38709769-5057A70D-A11D-485D-854D-866DE84F8D68Q38911701-E0581679-AF63-48B7-A20B-D8655882447AQ38911714-8C9CC6F2-5BF9-4863-B07F-FD761A1C2158Q38935811-0E1AE54C-7944-4566-A949-68FBF7863C4AQ39551157-D7752A7E-C2C4-41DB-8782-3965E5B6E4FCQ40951718-95C9F679-C98E-44AC-82C1-B12FC73ED407Q44238580-5BD0D8E9-3896-4826-BBC4-B00EB21001D5Q47743983-01E64F7F-AA07-496F-B5F3-0740CC34818AQ47788434-9DD3038D-F907-4774-84F4-C95DA5A807E1Q53967926-236CA6F4-8845-42F0-926D-1F30991382B4Q54958407-C4BE93F9-31AA-47DC-8548-DD35641E785B
P2860
Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@ast
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@en
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@en-gb
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@nl
type
label
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@ast
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@en
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@en-gb
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@nl
prefLabel
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@ast
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@en
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@en-gb
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@nl
P2093
P2860
P921
P3181
P356
P1476
Monocyte chemotactic protein-2 ...... diated HIV-1 entry/replication
@en
P2093
C J Raport
J A Turpin
J J Oppenheim
O M Howard
P2860
P304
P3181
P356
10.1074/JBC.273.8.4289
P407
P577
1998-02-20T00:00:00Z